LianBio announced that it has provided notification to The Nasdaq Stock Market of its intent to delist the Company’s American Depositary Shares, each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 with the Securities and Exchange Commission and Nasdaq relating to the voluntary delisting of its ADSs on or about March 11, 2024. Following the delisting, any trading in the Company’s ADSs would only occur in privately negotiated sales and potentially on an over-the-counter market. The Company expects that its ADSs will be quoted on a market operated by OTC Markets Group Inc. so that a trading market may continue to exist for its ADSs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LIAN:
- LianBio ADR Initiates Wind-Down and Announces Special Dividend
- LianBio board declares special cash dividend of $4.80 per share
- LianBio to commence wind down of operations, sale of remaining assets
- LianBio Announces Completion of Strategic Review
- The biopharmaceuticals stocks to own in 2024, according to BofA
